Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of IV Lanadelumab in Healthy Volunteers
NCT04503603Phase 1Completed
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing Lanadelumab 300 mg with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Change From Baseline in Laboratory Parameters and 12 more. Started Aug 2020; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04503603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04503603.